agonists

EMA review of suicide risk for Ozempic, Saxenda extended to other GLP-1 receptor agonists | Biospace

by
Pictured: The EMA building at its old headquarters in London/iStock, Lubo Ivanko

Pictured: The EMA building at its old headquarters in London/iStock, Lubo Ivanko The European Medicines Agency has extended its review of a potential suicide risk associated with Novo Nordisk’s Ozempic and Saxenda to other GLP-1 receptor agonists used for weight loss and the treatment of type 2 diabetes. The review was initiated by the Icelandic … Read more

CB2R agonists in clinics: a treasure chest for treating inflammatory diseases

by
CB2R agonists in clinics: a treasure chest for treating inflammatory diseases

Researchers give an update on clinical trials with CB2R agonists and their potential for the treatment of inflammatory diseases Activation of cannabinoid receptor type 2 (CB2R) has great potential for the treatment of diseases with an inflammatory component. This G protein-coupled receptor (GPCR) is a key element of the endocannabinoid system (ECS), an important lipid … Read more